Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Results from TAILORx trial presented at ESMO 2019
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
PROs encourage patient-centred cancer care
The benefits of adoptive T-cell therapy—where T-cells are given to induce a specific immune response—are moving closer to reality for patients with solid tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
